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Abstract: Recent research has investigated the use of Acoustic Emission (AE) monitoring of patients 
with Total Joint Replacement (TJR) implants. This technique involves using a set of four passive 
ultrasonic receivers to monitor the acoustic events that are created when a TJR implant is articulated 
through a range of motion. Both in-vitro and in-vivo monitoring of implants is possible. The soft-tissue 
attenuation characteristics are a very important aspect of how these two signal types are related as the aim 
of AE monitoring is to provide in-vivo diagnosis of implant degradation. This manuscript presents the 
results of in-vivo monitoring of patients with Total Hip Replacement (THR) implants. The corresponding 
Bode plots are presented to approximate the soft tissue attenuation characteristics. Overall averages are 
taken across 45 patient data sets and each of the four sensors, located against the skin surface, from the 
greater trochanter to mid-femur. Each sensor set is also analysed individually to delineate different 
tissues attenuation at the different locations. These results of this research can be used to determine the 
maximum likely frequency of interest present on the skin surface during AE monitoring, even if higher 
frequencies may be observed in-vitro. 
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Signal Analysis, Bode Plot, Frequency Spectrum, Attenuation Observations, Acoustic Emissions, 
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1. INTRODUCTION 
The number of total knee replacements performed in the U.S. 
will leap by 673% - reaching 3.48 million - by the year 2030, 
and hip replacements will increase by 174% to 572,000 
(Kurtz et al., 2003), largely due to demographic ageing 
(NZOA, 2003). Total joint replacement (TJR) surgery is 
typically the last resort for people with osteoarthritis (OA), 
also known as degenerative joint disease. TJR surgery is 
extremely successful (~90%), but these joints need to be 
replaced due to wear and/or premature loosening of the 
implant after 10-15 years (Kurtz et al., 2003; NZOA, 2003). 
The more primary joint replacements surgeries there are, the 
more revision TJR surgeries there will be all else equal, thus 
creating a significant and increasing cost, in both dollars and 
use, of scarce surgical services.  
With an epidemic of degenerative joint disease occurring, 
there is a huge challenge to find and implement effective 
screening programmes for detecting early TJR wear or 
failure, and clear diagnostic indicators for orthopaedic 
surgeons to properly manage revision surgery (NZOA, 2003; 
Browne et al., 2005). Early diagnosis of impending failure 
can save significant time, cost and more serious surgery. 
Currently, there are no reliable, non-traumatic and non-
invasive methods to monitor the healing process or loosening 
status after TJR. 
Research over the past 15-20 years has investigated acoustic 
emission (AE) monitoring to provide insight into implant 
condition and provide early detection of wear and loosening 
(Browne et al., 2005). AE monitoring devices use passive 
ultrasonic receivers to record high frequency vibrations 
emitted by the implant and correlate the recorded signal with 
clinical outcomes. The ultrasonic signals are typically 
characterised on frequency content or signal characteristics 
(short-duration high amplitude events/long-duration, lower 
amplitude events). These AE signals can be correlated with 
events, such as micro-scale brittle breakages of bone or bone 
cement, or vibrations due to wear and/or wear debris within 
the bearing surface between the femoral and acetabular 
components. Previous in-vitro and in-vivo studies 
demonstrate the potential AE frequency range of interest 
varies significantly (up to 1MHz in-vitro, but only up to 
50kHz for in-vivo tests on the skin surface) due to attenuation 
of vibrations through tissue (Browne et al., 2005) and there 
has been no research explicitly looking at the tissue 
attenuation characteristics. Moreover, AE monitoring devices 
typically utilise a single sensor located near the greater 
trochanter to determine joint condition. 
Recent research has developed an AE prototype diagnostic 
tool to assess implant designs and materials. The prototype 
includes four ultrasonic sensors placed against the skin, 
between the greater trochanter and the mid femur. The 
additional information from the multiple sensors and relative 
  
     
 
signal strength at each location can determine likely vibration 
sources (acetabular cup, bearing surface or femoral stem) and 
lead to clinical diagnosis. The technology can be applied to 
cemented versus uncemented components, and the 
performance of metal-on-plastic, metal-on-metal, and 
ceramic-on-ceramic bearing surfaces, and combinations 
thereof. This manuscript aims to investigate the range of 
frequencies observed on the skin surface during patient 
testing and to develop a soft tissue attenuation model. 
2. METHODS 
An AE prototype was used to undertake in-vivo monitoring of 
patients with Total Hip Replacement (THR) implants. The 
prototype consisted of four passive ultrasonic receivers, each 
with a resonant frequency of 25kHz.  The ultrasonic sensors 
were placed against the skin, between the greater trochanter 
and the mid femur The data from each sensor was 
simultaneously recorded at 100kHz as the patients undertook 
a range of standard orthopaedic test motions. These included 
standing from sitting in a chair, dropping from standing to 
crouching, and walking up stairs. The recording system was 
set to trip and record a data frame in response to any sensor 
exceeding a nominal voltage threshold. A total of 45 patients 
were tested, with some patients having unilateral implants 
and others having bilateral implants. Those with bilateral 
implants had both hip implants monitored independently. 
This research evaluates this prototype data. The main goal is 
to assess concept feasibility. In particular, it seeks to 
determine the transfer function and attenuation properties 
between the impulse sources and the measured response at 
the sensors. These first analyses will show the feasibility of 
the overall concept. 
The analysis methodology is focused on first investigating 
the time domain response and determining whether intra-
patient repeatability is possible across the range of patient 
input actions (standing from sitting etc.). The signals are then 
evaluated individually in the frequency domain by the use of 
Fourier transforms. Finally, Bode plots are generated in an 
overall average sense and on a per-sensor basis, to determine 
tissue attenuation characteristics. In these Bode plots the 
output signal frequency spectrum is used to approximate the 
transfer function based on the assumption that the signal 
generation at the source can be modelled as an impulse input 
with broad input frequency content. 
3. RESULTS 
3.1  Time Domain Results of Patient Trials 
Fig. 1 presents a typical time-domain response of a patient 
trial. In some cases the source of the vibration can be 
indicated by a phase delay between when the signal is 
detected at each of the four sensors. In Fig. 1 it is evident that 
the likely source of the vibration is at the lower end of the 
implant and may be due to loosening of the femoral 
component. This observation is due to the vibration being 
first detected on the lower sensor, followed by the upper 
sensors. 
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Fig. 1. Typical time-domain response of an in-vivo patient 
trial. Vertical scale is volts, with a nominal voltage offset for 
each sensor to indicate position. 
Intra-patient repeatability is a key aspect of the response and 
a very important consideration if discrimination between 
failure modes is to be achieved. Fig. 2 presents a group of 
repeated tests for a patient undertaking a range of different 
tasks. It is evident that intra-patient repeatability is present 
for this patient and that even a range of different tasks leads 
to the same distinct dominance of one sensor. Note that 
Figure 2 represents a different patient to those in Figure 1.  
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Fig. 2. Repeated tests for a single patient to test intra-patient 
variability. As in Fig. 1, the vertical scale is volts, with a 
nominal voltage offset for each sensor to indicate position. 
3.2  Frequency Domain Results 
The time domain results for each patient were obtained 
through a discrete fourier transform. It was initially expected 
that most of the content in the signals would be well above 
the range of human hearing and generally at least 20kHz. 
However, the patient trial results showed that the signals 
were almost exclusively below 15kHz, with a vast majority 
  
     
 
of the signal below 5kHz. Fig. 3 presents a typical frequency 
domain magnitude plot of the measured in-vivo patient data.  
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Fig. 3. Frequency domain magnitude of in-vivo signals. Note 
that the data and series colours correspond to those presented 
in Fig. 2. 
It is expected that the actual in-vitro acoustic emissions at the 
implant will produce much higher frequencies than those 
observed in Fig. 3. When considering an event such as the 
breakage of bone or bone cement, or impacting of the implant 
bearing surfaces, it is expected that the signal generation 
could be considered as an impulse input. Therefore, the range 
of frequency content produced at the implant would be 
expected to cover a much wider frequency band than seen at 
the skin surface. Therefore, it was considered that the 
frequency range at the skin surface, if averaged over a range 
of patients, would provide a good estimate of the overall 
tissue attenuation/transmission properties. 
Hence, the frequency spectrum was plotted on a log-log scale 
as a Bode plot, typical for investigating a transfer function. 
Fig. 4 presents the Bode plot for a total of 45 patients. Fig. 4 
shows one line per patient for each of the 45 of the patients in 
the clinical trial. To produce this plot, the data in each 
channel was averaged (all 200 data point frames were 
averaged together), and the channels were also averaged 
together. This approach gave one line per patient, as shown in 
Fig. 4. Note that it is assumed that the input is an impulse. 
Therefore, the output spectrum can be directly considered as 
the transfer function. 
It is evident in Fig. 4 that there is a consistent fall-off in 
magnitude beyond 1kHz. Due to the consistent nature of this 
drop in magnitude and the assumption of an impulse input, it 
is assumed that this fall-away represents the soft-tissue 
attenuation. However, also evident in Fig. 4 is the variable 
signal amplitude at low frequencies with values ranging from 
-30 to -55 dB. This observation can be explained easily by 
considering that all of the signal magnitudes are variable and 
that the overall magnitude of the acoustic events at the 
implant varies accordingly. Equally, it may represent inter-
patient variability. 
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Fig. 4. Bode plot of the in-vivo patient data.  
To eliminate this affect, all of the responses on the Bode plot 
of Fig. 4 were normalised to have the same initial magnitude. 
This normalisation enables easier comparison of the relative 
attenuation at higher frequencies. The results are presented in 
Fig. 5. 
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Fig. 5. Bode plot of the in-vivo patient data, with responses 
normalised to the same initial magnitude. 
It can be seen in Fig. 5 that the exact attenuation 
characteristics appear more variable, but that the relative 
frequency content drops off significantly at the higher 
frequencies, irrespective of peak signal magnitude. 
It should also be noted that the responses in Figs. 4 and 5 are 
averaged across all patient trials and all sensor locations. It is 
expected that the signal attenuation characteristics will very 
across each sensor as there is different underlying tissue at 
each sensor location. It might be expected that the sensor 
placed near the greater trochanter will exhibit less attenuation 
as the skin surface is near a bony landmark and there is less 
soft tissue for the signal to transmit through. Conversely, the 
sensors on the mid-femur have much more muscle, fascia, 
and soft tissue to attenuate the response. However, given that 
the input magnitude is not known and there is no way of 
normalising to get the true transmission, there are some 
limitations to this analysis and care should be taken when 
considering the results. 
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a) Response of sensor 1 (top) 
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b) Response of sensor 2 
     
101 102 103 104 105
-2.8
-2.6
-2.4
-2.2
-2
-1.8
-1.6
-1.4
-1.2
-1
frequency [Hz]
m
a
gn
itu
de
 
c) Response of sensor 3 
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d) Response of sensor 4 (bottom) 
Fig. 6. Bode plots of the in-vivo patient data, split into 
individual sensors, with responses normalised to the same 
initial magnitude. 
Figs. 6a-d present the attenuation characteristics for each 
sensor independently. The response of each sensor is plotted 
for each patient and normalised to the same overall 
magnitude using the same approach as that of Fig. 5. Fig. 6 is 
essentially Fig. 5, but split into the responses from each of 
the four sensors. Also shown in Fig. 6 are the median, 25th 
and 75th percentile lines to give an indication of the spread of 
the data. It is evident in Fig. 6 that the attenuation 
characteristics are broadly similar for all of the sensor 
locations. Specific differences can be attributed to differences 
in the underlying soft tissue make-up at the sensor locations 
or, more specifically, inter-patient variability. 
To better compare the attenuation characteristics of each 
sensor location, all of the median, 25th and 75th percentile 
lines from Figs. 6a-d have been reproduced on the same axes 
in Fig. 7. It can be seen in Fig. 7 that the sensors do show 
some clear differences in their specific attenuation 
characteristics. Sensors 1 and 3 show similar attenuation 
characteristics above 20kHz, with both of these sensors 
showing much lower transmission than sensors 2 and 4. 
Sensor 1 shows the lowest transmission of any of the sensors 
between 100Hz and 10kHz. This is not an expected result, as 
this sensor is up near the greater trochanter and it is assumed 
that the greatest transmission would occur at this point. 
However, there may be other influencing factors, such as less 
inherent noise generation at the upper acetabular components, 
compared with the lower femoral components. 
Overall, all sensors show a notable drop-off in frequency 
content above 10kHz. It should be noted that this observation 
of lower frequency magnitude in this range may be a 
combination of tissue attenuation and the specific 
characteristics of the ultrasonic receivers. However, the 
ultrasonic receivers had a design resonant frequency of 
25kHz, so it is expected that any frequency content present at 
the skin surface in this range (10-25kHz) would be well 
detected by the sensors. Therefore, it is reasonable to 
conclude that even though there may be much higher 
frequencies created during articulation of the implant 
interfaces at the source, that very little of these higher 
frequency vibrations are transmitted to the skin surface. 
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Fig. 7. Combined Bode plot of the in-vivo patient data, split 
into individual sensors, with responses normalised to the 
  
     
 
same initial magnitude. Each sensor is represented by the 
25th, 50th (median) and 75th percentile. 
3.3  Transfer Function Approximation 
To extend the analyses, it is useful to develop an approximate 
transfer function of the soft tissue. This transfer function will 
enable approximation of the likely in-vivo frequencies at the 
skin surface that can be expected for any observed frequency 
range during in-vitro testing of the implant. To investigate the 
actual transfer function, the results of Fig. 7 are presented 
again in Fig. 8, but without the normalisation to the same 
initial magnitude. It is evident in Fig. 8 that there is a notable 
spread as inter-patient variability on the data and that any 
fitted transfer function must be used with caution. However, 
the overall results of significant attenuation over 10kHz 
remains valid. 
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Fig. 8. Combined Bode plot of the in-vivo patient data, split 
into individual sensors. Each sensor is represented by the 
25th, 50th (median) and 75th percentile. 
Fig. 9 presents the transfer function fitted to the patient 
results. It should be noted that while there is a phase plot in 
Fig. 9, no phase plots are presented for the patient data. The 
input for the patient data is assumed to be essentially an 
impulse input and therefore there is no inherent definition of 
phase as applied to the patient data, where analytical Bode 
plots assume sine wave inputs. If the attenuation 
characteristics were determined from sinusoidal input 
waveforms, then phase plots could be included. However, 
given the nature of the system, when the phase response is 
plotted for the patient data, it appears as a very noisy data set, 
based around a central value of zero. 
Equation 1 describes the empirically fitted transfer function, 
which is plotted in Fig. 9. Equation 1 is determined based 
upon a best-fit to the overall patient data and can be used as a 
rough approximation to the tissue attenuation characteristics. 
Ko is a scaling constant, while zi are the zeroes of the transfer 
function and pi are the pole locations.  
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Fig. 9. Analytical transfer function fitted to the patient 
results. 
 
4. DISCUSSION 
The development of an Acoustic Emission monitoring device 
has the potential to be a very useful diagnostic tool for 
orthopaedic surgeons. The underlying premise of the AE 
monitoring device is that different wear and failure modes of 
the implant will produce unique frequency signatures, which 
can be identified during in-vitro testing of the implants. The 
AE monitoring device can then be utilised for in-vivo patient 
testing, when the passive ultrasonic receivers can be placed 
against the skin surface. When considering the correlation 
between the frequency response in-vitro and in-vivo, the 
tissue attenuation properties must be considered. These 
results of Figs. 3-8 show that while there may be high 
frequency vibrations present within the response of the 
implant, these high frequencies are heavily attenuated by the 
soft tissue. Therefore, the maximum frequency of interest at 
the skin surface is approximately 20kHz, and in practice most 
of the content is well below 10kHz. 
It should be noted that much of the data presented here dates 
back to orthopaedic implants, utilising primarily the metal-
on-plastic and metal-on-metal bearing surfaces. Newer, 
ceramic-on-ceramic implants have the potential to produce 
higher frequency vibrations as well as audible squeaking of 
the implants. Ongoing research is undertaking a new range of 
patient trials, testing patients with a range of implant bearing 
surfaces. It should also be noted that the source of vibration 
from the implants is not restricted to just the bearing 
interface. Any loosening of the femoral head on the morse 
taper, looseing of the femoral stem within the femur, or 
loosening of the acetabular components will all produce a 
vibration response. The ongoing research attempts to 
correlate the vibration measurements with diagnostic 
indicators via two key, parallel methods. In-vitro testing is 
being undertaken to identify any unique frequency responses 
that can be attributed to movement of different implant 
interfaces. These identified frequencies can then be 
considered with respect to the attenuation model presented 
here, to estimate the in-vivo frequencies of interest. 
  
     
 
It should be noted that these results are specific to hip 
replacement implants, but that a similar approach could be 
used for knee replacements. However, the attenuation 
properties will likely be quite different due to the proximity 
of the boney landmarks to the skin surface. 
5. CONCLUSIONS 
This manuscript presents the in-vivo patient testing results of 
an AE monitoring device prototype. Assuming that the 
vibration range produced within the implant can be 
approximated as an impulse, with broad frequency content, 
the output frequency spectrum has been used to approximate 
the soft tissue attenuation characteristics. The results indicate 
that the maximum frequencies present at the skin surface are 
approximately 20kHz, with a vast majority of the signal 
being well below 10kHz. Ongoing research continues to 
investigate and further verify the frequencies of interest in the 
response of orthopaedic implants. 
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